The inhibitory effect of opioids on HepG2 cells is mediated via interaction with somatostatin receptors

European Journal of Pharmacology

Volumn 555, Issue 1, 2007, Pages 1-7

  Notas, George ^a   Kampa, Marilena ^a   Nifli, Artemissia Phoebe ^a   Xidakis, Kostas ^a   Papasava, Despoina ^a   Thermos, Kyriaki ^a   Kouroumalis, Elias ^a   Castanas, Elias ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

HepG2 cell; Opioid (ethylketocyclazocine); Opioid receptors (delta, mu, kappa); Somatostatin receptor; Tyrosine phosphatase

Indexed keywords

DIPRENORPHINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2 DEXTRO ALANINE 5 DEXTRO LEUCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; ETHYLKETAZOCINE; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; OCTREOTIDE; OPIATE AGONIST; OPIATE DERIVATIVE; OPIATE RECEPTOR; PROTEIN TYROSINE PHOSPHATASE; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR;

ANALGESIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN SECRETION; SIGNAL TRANSDUCTION;

ANALGESICS, OPIOID; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DIPRENORPHINE; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; ENKEPHALIN, LEUCINE-2-ALANINE; ETHYLKETOCYCLAZOCINE; HUMANS; NARCOTIC ANTAGONISTS; OCTREOTIDE; RECEPTORS, OPIOID; RECEPTORS, SOMATOSTATIN; RNA, MESSENGER; SOMATOSTATIN;

EID: 33845798389     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.10.018     Document Type: Article

References (33)

1. Bruix J., Sherman M., Llovet J.M., Beaugrand M., Lencioni R., Burroughs A.K., Christensen E., Pagliaro L., Colombo M., and Rodes J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol. 35 (2001) 421-430
2. Bulenger S., Marullo S., and Bouvier M. Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol. Sci. 26 (2005) 131-137
3. Castanas E., Bourhim N., Giraud P., Boudouresque F., Cantau P., and Oliver C. Interaction of opiates with opioid binding sites in the bovine adrenal medulla: I. interaction with delta and mu sites. J. Neurochem. 45 (1985) 677-687
4. Castanas E., Bourhim N., Giraud P., Boudouresque F., Cantau P., and Oliver C. Interaction of opiates with opioid binding sites in the bovine adrenal medulla: II. interaction with kappa sites. J. Neurochem. 45 (1985) 688-699
5. Chiodera P., Gnudi A., Bianconi L., Capretti L., Fagnoni F., Volpi R., and Coiro V. Naloxone abolishes the inhibiting effect of somatostatin on the release of oxytocin evoked by insulin-induced hypoglycemia in humans. Metabolism 38 (1989) 709-711
6. Dimitroulopoulos D., Xinopoulos D., Tsamakidis K., Zisimopoulos A., Andriotis E., Markidou S., Panagiotakos D., Chrysohoou C., Bazinis A., and Paraskevas E. The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology 49 (2002) 1245-1250
7. Falk P.M., Sabater R.T., and Carballo Jr. D.D. Response of the human hepatic tissue cultures Hep-G2 and WRL-68 to cocaine. J. Pharmacol. Toxicol. Methods 33 (1995) 113-120
8. Ghosh S., Geller E.B., and Adler M.W. Interaction of cholecystokinin and somatostatin with a selective mu-opioid agonist and mu- and kappa-antagonists in thermoregulation. Brain Res. 745 (1997) 152-157
9. Hatzoglou A., Ouafik L., Bakogeorgou E., Thermos K., and Castanas E. Morphine cross-reacts with somatostatin receptor SSTR2 in the T47D human breast cancer cell line and decreases cell growth. Cancer Res. 55 (1995) 5632-5636
10. Hatzoglou A., Bakogeorgou E., Hatzoglou C., Martin P.M., and Castanas E. Antiproliferative and receptor binding properties of alpha- and beta-casomorphins in the T47D human breast cancer cell line. Eur. J. Pharmacol. 310 (1996) 217-223
11. Hatzoglou A., Bakogeorgou E., Papakonstanti E., Stournaras C., Emmanouel D.S., and Castanas E. Identification and characterization of opioid and somatostatin binding sites in the opossum kidney (OK) cell line and their effect on growth. J. Cell. Biochem. 63 (1996) 410-421
12. Hatzoglou A., Kampa M., and Castanas E. Opioid-somatostatin interactions in regulating cancer cell growth. Front. Biosci. 10 (2005) 244-256
13. Horvath A., Folhoffer A., Lakatos P.L., Halosz J., Illyes G., Schaff Z., Hantos M.B., Tekes K., and Szalay F. Rising plasma nociceptin level during development of HCC: a case report. World J. Gastroenterol. 10 (2004) 152-154
14. Jairaj M., Watson D.G., Grant M.H., and Skellern G.G. The toxicity of opiates and their metabolites in HepG2 cells. Chem. Biol. Interact. 146 (2003) 121-129
15. Jordan B.A., Trapaidze N., Gomes I., Nivarthi R., and Devi L.A. Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 343-348
16. Kampa M., Bakogeorgou E., Hatzoglou A., Damianaki A., Martin P.M., and Castanas E. Opioid alkaloids and casomorphin peptides decrease the proliferation of prostatic cancer cell lines (LNCaP, PC3 and DU145) through a partial interaction with opioid receptors. Eur. J. Pharmacol. 335 (1997) 255-265
17. Kampa M., Loukas S., Tsapis A., and Castanas E. Receptorphin: a conserved peptide derived from the sequence of the opioid receptor, with opioid displacement activity and potent antiproliferative actions in tumor cells. BMC Pharmacol. 1 (2001) 9
18. Konagaya T., Kusugami K., Yamamoto H., Nishio Y., Kaneko H., Nagai H., and Mitsuma T. Effect of intragastric administration of beta-endorphin on thyrotropin-releasing hormone and somatostatin release into gastric lumen of rats. J. Gastroenterol. 33 (1998) 27-31
19. Kotb H.I., El-Kady S.A., Emara S.E., Fouad E.A., and El-Kabsh M.Y. Pharmacokinetics of controlled release morphine (MST) in patients with liver carcinoma. Br. J. Anaesth. 94 (2005) 95-99
20. Kouroumalis E., Skordilis P., Thermos K., Vasilaki A., Moschandrea J., and Manousos O.N. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 42 (1998) 442-447
21. Liapakis G., and Thermos K. Characterization of [125I]Tyr11-somatostatin binding sites in the rabbit retina. Neuropeptides 21 (1992) 13-19
22. Liu H.L., Huo L., and Wang L. Octreotide inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells. Acta Pharmacol. Sin. 25 (2004) 1380-1386
23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
24. Notas G., Kolios G., Mastrodimou N., Kampa M., Vasilaki A., Xidakis C., Castanas E., Thermos K., and Kouroumalis E. Cortistatin production by HepG2 human hepatocellular carcinoma cell line and distribution of somatostatin receptors. J. Hepatol. 40 (2004) 792-798
25. Pfeiffer M., Koch T., Schroder H., Laugsch M., Hollt V., and Schulz S. Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J. Biol. Chem. 277 (2002) 19762-19772
26. Raderer M., Hejna M.H., Muller C., Kornek G.V., Kurtaran A., Virgolini I., Fiebieger W., Hamilton G., and Scheithauer W. Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. Int. J. Oncol. 16 (2000) 1197-1201
27. Shook J.E., Pelton J.T., Lemcke P.K., Porreca F., Hruby V.J., and Burks T.F. Mu opioid antagonist properties of a cyclic somatostatin octapeptide in vivo: identification of mu receptor-related functions. J. Pharmacol. Exp. Ther. 242 (1987) 1-7
28. Stirnweiss J., Hartrodt B., Greksch G., Sturzebecher U., Bohmer F.D., Neubert K., and Liebmann C. Tyr-c[D-Orn-Tyr(Bzl)-Pro-Gly]: a novel antiproliferative acting somatostatin receptor agonist with mu-opioid receptor-sensitizing properties. Br. J. Pharmacol. 140 (2003) 13-22
29. Szalay F., Hantos M.B., Horvath A., Lakatos P.L., Folhoffer A., Dunkel K., Hegedus D., and Tekes K. Increased nociceptin/orphanin FQ plasma levels in hepatocellular carcinoma. World J. Gastroenterol. 10 (2004) 42-45
30. Terrillon S., and Bouvier M. Roles of G-protein-coupled receptor dimerization. EMBO Rep. 5 (2004) 30-34
31. Vermes I., Haanen C., Steffens-Nakken H., and Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods 184 (1995) 39-51
32. Wang C., Tang C., and Tang L. Inhibition effects of octreotide on the growth of hepatocellular carcinoma in vitro and in vivo. Zhonghua Yixue Zazhi 81 (2001) 1194-1197
33. Yuen M.F., Poon R.T., Lai C.L., Fan S.T., Lo C.M., Wong K.W., Wong W.M., and Wong B.C. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 36 (2002) 687-691